Dark

Check out our Level2View

AVRO
AVROBIO, Inc. Common Stock
stock NASDAQ

Inactive

Jun 20, 2024

16.80USD-1.408%(-0.24)17,235

Pre-market

0.00USD-100.000%(-17.04)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 6, 2022

07:07AM EST Mizuho Maintains Buy on Avrobio, Lowers Price Target to $6 Benzinga

07:00AM EST AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Jan 5, 2022

11:07AM EST Stocks That Hit 52-Week Lows On Wednesday Benzinga

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2022 Benzinga

10:06AM EST Analyst Ratings For Avrobio Benzinga

09:53AM EST Barclays Maintains Overweight on Avrobio, Lowers Price Target to $6 Benzinga

08:41AM EST Morgan Stanley Maintains Equal-Weight on Avrobio, Lowers Price Target to $3 Benzinga

05:36AM EST BTIG Downgrades Avrobio to Neutral Benzinga

04:40AM EST Needham Maintains Buy on Avrobio, Lowers Price Target to $8 Benzinga

Jan 4, 2022

02:41PM EST Mid-Afternoon Market Update: Dow Jumps 250 Points; Avrobio Shares Slide Benzinga

12:17PM EST Mid-Day Market Update: Nasdaq Dips 250 Points; TherapeuticsMD Shares Surge Benzinga

10:58AM EST Stocks That Breached 52-Week Lows Today Benzinga

10:10AM EST Mid-Morning Market Update: Markets Mostly Higher; ISM Manufacturing Index Drops To 58.7 Benzinga

08:11AM EST The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives Benzinga

07:08AM EST Avrobio Shares to Resume Trading at 7:30 AM ET Benzinga

07:02AM EST AVROBIO Announces Fabry Disease Program To Be Deprioritize, Co. 'shifting focus to other clinical-stage programs in lysosomal disorder pipeline' Benzinga

Nov 24, 2021

07:02AM EST AVROBIO Highlights Presentation Of Clinician Experience With FAB-GT Clinical Trial And Updated Safety Data For Investigational Gene Therapies In Fabry Disease And Gaucher Disease Type 1 Benzinga

Nov 19, 2021

10:09AM EST Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021 Benzinga

07:24AM EST Morgan Stanley Downgrades Avrobio to Equal-Weight, Lowers Price Target to $7 Benzinga

Nov 9, 2021

11:45AM EST Jasper Therapeutics Announces Research Collaboration With AVROBIO To Evaluate JSP191 As Conditioning Agent In Clinical Studies Of Ex Vivo Lentiviral Gene Therapy Benzinga

Nov 5, 2021

07:00AM EDT AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Nov 4, 2021

07:38AM EDT Avrobio Q3 EPS $(0.75) Up From $(1.01) YoY Benzinga

Nov 3, 2021

09:15AM EDT AVROBIO Receives Rare Pediatric Disease Designation From The U.S. FDA For AVR-RD-05, A Gene Therapy For Mucopolysaccharidosis Type II Or Hunter Syndrome Benzinga

Oct 22, 2021

07:36AM EDT The Daily Biotech Pulse: Athira CEO Resigns Over Doctored Research, Merck's Keytruda Snags First Approval For Breast Cancer In Europe, Minerva And Xilio IPOs Benzinga

Oct 20, 2021

07:17AM EDT AVROBIO To Present At The Jefferies Virtual Gene Therapy/Editing Summit Benzinga

Oct 18, 2021

07:34AM EDT The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs Benzinga

Oct 12, 2021

08:07AM EDT Morgan Stanley Maintains Overweight on Avrobio, Lowers Price Target to $25 Benzinga

Oct 6, 2021

07:07AM EDT AVROBIO To Present New Clinical And Preclinical Data Across Multiple Programs At The ESGCT 28th Annual Congress Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 19, 2021

10:57AM EDT The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 12, 2021

08:09AM EDT The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma Benzinga

Aug 11, 2021

08:14AM EDT The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering Benzinga

Aug 10, 2021

07:55AM EDT The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts Benzinga

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

07:49AM EDT Avrobio Q2 EPS $(0.74) Up From $(0.80) YoY Benzinga

Aug 4, 2021

07:00AM EDT AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 16, 2021

08:34AM EDT Morgan Stanley Maintains Overweight on Avrobio, Lowers Price Target to $29 Benzinga

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jun 16, 2021

05:02AM EDT 44 Biggest Movers From Yesterday Benzinga

Jun 15, 2021

10:24AM EDT Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021 Benzinga

08:07AM EDT The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda Benzinga

06:41AM EDT BTIG Initiates Coverage On Avrobio with Buy Rating, Announces Price Target of $23 Benzinga

May 27, 2021

06:08AM EDT Needham Maintains Buy on Avrobio, Announces $28 Price Target Benzinga

May 14, 2021

07:27AM EDT Morgan Stanley Maintains Overweight on Avrobio, Lowers Price Target to $31 Benzinga

May 13, 2021

07:08AM EDT Avrobio Q1 EPS $(0.65) Up From $(0.77) YoY Benzinga

May 12, 2021

08:57AM EDT The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron Benzinga

May 11, 2021

07:54AM EDT The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings Benzinga

May 7, 2021

07:40AM EDT The Daily Biotech Pulse: Split Verdict For Chemocentryx, NKarta-CRISPR In Cell Therapy Collaboration, Orphazyme's Clinical Trial Setback, 2 IPOs Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

May 5, 2021

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

May 4, 2021

08:10AM EDT The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data Benzinga

May 3, 2021

02:40PM EDT Mid-Afternoon Market Update: Crude Oil Rises 1.5%; AVROBIO Shares Plummet Benzinga

12:13PM EDT Mid-Day Market Update: Nasdaq Drops 50 Points; Ocugen Shares Spike Higher Benzinga

10:26AM EDT SVB Leerink Maintains Market Perform on Avrobio, Lowers Price Target to $10 Benzinga

09:42AM EDT Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy Benzinga

07:07AM EDT AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease Benzinga

Apr 20, 2021

08:07AM EDT The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex Benzinga

Apr 19, 2021

10:18AM EDT Stocks That Hit 52-Week Lows On Monday Benzinga

Mar 18, 2021

10:26AM EDT Avrobio shares were trading lower after the company reported Q4 EPS results down from last year. Benzinga

07:03AM EDT Avrobio Q4 EPS $(0.73) Down From $(0.72) YoY Benzinga

Mar 9, 2021

10:07AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2021 Benzinga

09:15AM EST Barclays Initiates Coverage On Avrobio with Overweight Rating, Announces Price Target of $23 Benzinga

Mar 2, 2021

01:13PM EST Stifel Initiates Coverage On Avrobio with Hold Rating, Announces Price Target of $14 Benzinga

Mar 1, 2021

12:00PM EST Avrobio's Cystinosis Gene Therapy Gets Orphan Drug Status In Europe Benzinga

07:04AM EST AVROBIO Receives Orphan Drug Designation From European Commission For AVRRD04, An Investigational Gene Therapy For Cystinosis Benzinga

Feb 8, 2021

08:07AM EST Avrobio Shares Rally On Fabry Disease Gene Therapy Encouraging Benefit In Early-Stage Study Benzinga

07:07AM EST AVROBIO Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial Benzinga

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Jan 19, 2021

07:10AM EST AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer Benzinga

Nov 20, 2020

08:06AM EST The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger Benzinga

Nov 19, 2020

04:10PM EST AVROBIO Announces Proposed Public Offering Of Common Stock Of $75M Of Stock Benzinga

Nov 17, 2020

08:32AM EST The Daily Biotech Pulse: Setback For Alkermes, Boston Scientific's Recall, ALX-Zymeworks Oncology Collaboration Benzinga

07:03AM EST AVROBIO Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline Benzinga

Nov 11, 2020

10:50AM EST Berenberg Initiates Coverage On Avrobio with Buy Rating, Announces Price Target of $27 Benzinga

Nov 5, 2020

07:18AM EST Avrobio Q3 EPS $(1.01) Down From $(0.57) YoY Benzinga

Oct 29, 2020

07:26AM EDT AVROBIO Receives Orphan Drug Designation from the European Commission for AVRRD01, an Investigational Gene Therapy for Fabry Disease Benzinga

Oct 13, 2020

08:24AM EDT Morgan Stanley Maintains Overweight on Avrobio, Lowers Price Target to $34 Benzinga

Oct 5, 2020

07:09AM EDT AVROBIO Announces Exclusive, Worldwide License Agreement And A Collaborative Research Funding Agreement With The University Of Manchester For An Investigational Lentiviral Gene Therapy For Mucopolysaccharidosis Type II, Or Hunter Syndrome Benzinga

Sep 28, 2020

07:01AM EDT AVROBIO Receives Orphan Drug Designation from the European Medicines Agency for AVR-RD-02, an Investigational Gene Therapy for Gaucher Disease Benzinga

Aug 7, 2020

07:24AM EDT AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Benzinga

Aug 6, 2020

11:13AM EDT Avrobio Earlier Reported Q2 Net Loss $28.8M vs Loss $16.1M In Same Qtr. Last Year Benzinga

Jul 15, 2020

09:49AM EDT Morgan Stanley Maintains Overweight on Avrobio, Lowers Price Target to $35 Benzinga

Share